The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06807424




Registration number
Help: Registration number
NCT06807424
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
29/01/2025
Date registered
Help: Date registered
4/02/2025
Date last updated
Help: Date last updated
3/11/2026

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Additional trial identifiers [1] 0 0
2024-517284-23-00
Additional trial identifiers [2] 0 0
77242113PSA3002
Universal Trial Number (UTN)
Trial acronym
ICONIC-PsA 2
Related trial records

Health condition
Health condition(s) studied:
Arthritis, Psoriatic 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Icotrokinra
Treatment: Drugs - Placebo

Experimental: Group I: Icotrokinra Dose 1 - Participants will receive icotrokinra Dose 1. Participants who have not discontinued will be eligible to enter a long term extension (LTE) and will continue to receive icotrokinra Dose 1.

Experimental: Group II: Icotrokinra Dose 2 - Participants will receive icotrokinra Dose 2. Participants who have not discontinued will be eligible to enter a LTE and will continue to receive icotrokinra Dose 2.

Placebo comparator: Group III: Placebo - Participants will receive placebo matched to icotrokinra and will cross over to receive icotrokinra Dose 1 or Dose 2 at Week 16. Participants who have not discontinued will be eligible to enter a LTE and will continue to receive icotrokinra Dose 1 or Dose 2.


Treatment: Drugs: Icotrokinra
Icotrokinra will be administered.

Treatment: Drugs: Placebo
Placebo will be administered.

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of Participants who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
Timepoint [1] 0 0
Week 16
Secondary outcome [1] 0 0
Proportion of Participants Who Achieved Psoriatic Area and Severity Index (PASI) 75 Response at Week 16 Among Participants with Baseline Body Surface Area (BSA) Greater Than Equal to (>=) 3 Percent (%) and With Baseline IGA Score of >=2
Timepoint [1] 0 0
Week 16
Secondary outcome [2] 0 0
Proportion of Participants Who Achieved PASI 90 Response at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Timepoint [2] 0 0
Week 16
Secondary outcome [3] 0 0
Proportion of Participants Who Achieved PASI 100 Response at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Timepoint [3] 0 0
Week 16
Secondary outcome [4] 0 0
Proportion of Participants with an Investigator Global Assessment (IGA) Psoriasis Score of 0 or 1 And >=2 Grade Improvement From Baseline at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Timepoint [4] 0 0
Week 16
Secondary outcome [5] 0 0
Proportion of Participants who Achieved an ACR 50 Response at Week 16
Timepoint [5] 0 0
Week 16
Secondary outcome [6] 0 0
Proportion of Participants who Achieved an ACR 70 Response at Week 16
Timepoint [6] 0 0
Week 16
Secondary outcome [7] 0 0
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score At Week 16
Timepoint [7] 0 0
From baseline up to Week 16
Secondary outcome [8] 0 0
Changes From Baseline in 36 Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
Timepoint [8] 0 0
From baseline up to Week 16
Secondary outcome [9] 0 0
Proportion of Participants With Resolution of Enthesitis at Week 16 Among Those With Enthesitis at Baseline
Timepoint [9] 0 0
Week 16
Secondary outcome [10] 0 0
Change From Baseline in Enthesitis Score at Week 16 in Participants With Enthesitis at Baseline
Timepoint [10] 0 0
Baseline and Week 16
Secondary outcome [11] 0 0
Proportion of Participants With Resolution of Dactylitis at Week 16 Among Those With Dactylitis at Baseline
Timepoint [11] 0 0
Week 16
Secondary outcome [12] 0 0
Change From Baseline in Dactylitis Score at Week 16 in Participants With Dactylitis at Baseline
Timepoint [12] 0 0
From baseline up to Week 16
Secondary outcome [13] 0 0
Proportion of Participants who Achieved Minimal Disease Activity (MDA) at Week 16
Timepoint [13] 0 0
Week 16
Secondary outcome [14] 0 0
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 16
Timepoint [14] 0 0
From baseline up to Week 16

Eligibility
Key inclusion criteria
* Have active psoriatic arthritis (PsA) despite current or previous use of greater than or equal to (>=) 1 of the following: a. Non-biologic disease-modifying antirheumatic drug (DMARD) therapy; b. Apremilast therapy; c. Biologic-agent (limited to only 1)
* Have a diagnosis of PsA for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening
* Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) >= 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
* Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
* Have active plaque psoriasis with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with psoriasis
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances
* Currently has a malignancy or has a history of malignancy within 5 years prior to screening
* Has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients
* Has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus, or Lyme disease
* Participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Ipswich Hospital - Ipswich
Recruitment hospital [2] 0 0
Rheumatology Research Unit - Maroochydore
Recruitment hospital [3] 0 0
Queen Elizabeth Hospital - South Woodville
Recruitment hospital [4] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [5] 0 0
Royal Darwin Hospital - Tiwi
Recruitment postcode(s) [1] 0 0
4305 - Ipswich
Recruitment postcode(s) [2] 0 0
4558 - Maroochydore
Recruitment postcode(s) [3] 0 0
5011 - South Woodville
Recruitment postcode(s) [4] 0 0
2065 - St Leonards
Recruitment postcode(s) [5] 0 0
0810 - Tiwi
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad de Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Ciudad de San Miguel de Tucuman
Country [18] 0 0
Argentina
State/province [18] 0 0
San Fernando
Country [19] 0 0
Brazil
State/province [19] 0 0
Belo Horizonte
Country [20] 0 0
Brazil
State/province [20] 0 0
Porto Alegre
Country [21] 0 0
Brazil
State/province [21] 0 0
São José do Rio Preto
Country [22] 0 0
Brazil
State/province [22] 0 0
São Paulo
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Plovdiv
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sliven
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Sofia
Country [26] 0 0
Canada
State/province [26] 0 0
Newfoundland and Labrador
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
China
State/province [29] 0 0
Beijing
Country [30] 0 0
China
State/province [30] 0 0
Changchun
Country [31] 0 0
China
State/province [31] 0 0
Changsha
Country [32] 0 0
China
State/province [32] 0 0
Chengdu
Country [33] 0 0
China
State/province [33] 0 0
Chongqing
Country [34] 0 0
China
State/province [34] 0 0
Dongguan
Country [35] 0 0
China
State/province [35] 0 0
Guangzhou
Country [36] 0 0
China
State/province [36] 0 0
Guiyang
Country [37] 0 0
China
State/province [37] 0 0
Hangzhou
Country [38] 0 0
China
State/province [38] 0 0
Jiaxing
Country [39] 0 0
China
State/province [39] 0 0
Jinhua
Country [40] 0 0
China
State/province [40] 0 0
Linfen
Country [41] 0 0
China
State/province [41] 0 0
Linyi
Country [42] 0 0
China
State/province [42] 0 0
Nanchang
Country [43] 0 0
China
State/province [43] 0 0
Nantong
Country [44] 0 0
China
State/province [44] 0 0
Pingxiang
Country [45] 0 0
China
State/province [45] 0 0
Shanghai
Country [46] 0 0
China
State/province [46] 0 0
Shenzhen
Country [47] 0 0
China
State/province [47] 0 0
Suzhou
Country [48] 0 0
China
State/province [48] 0 0
Taiyuan
Country [49] 0 0
China
State/province [49] 0 0
Wenzhou
Country [50] 0 0
China
State/province [50] 0 0
Xi'an
Country [51] 0 0
Czechia
State/province [51] 0 0
Brno
Country [52] 0 0
Czechia
State/province [52] 0 0
Breclav
Country [53] 0 0
Czechia
State/province [53] 0 0
Hlucín
Country [54] 0 0
Czechia
State/province [54] 0 0
Ostrava
Country [55] 0 0
Czechia
State/province [55] 0 0
Prague
Country [56] 0 0
Czechia
State/province [56] 0 0
Uherské Hradište
Country [57] 0 0
Czechia
State/province [57] 0 0
Zlín
Country [58] 0 0
Denmark
State/province [58] 0 0
Aarhus N
Country [59] 0 0
Denmark
State/province [59] 0 0
Esbjerg
Country [60] 0 0
Denmark
State/province [60] 0 0
Frederiksberg
Country [61] 0 0
Denmark
State/province [61] 0 0
Herning
Country [62] 0 0
Denmark
State/province [62] 0 0
Svendborg
Country [63] 0 0
Denmark
State/province [63] 0 0
Vejle
Country [64] 0 0
Germany
State/province [64] 0 0
Berlin
Country [65] 0 0
Germany
State/province [65] 0 0
Cologne
Country [66] 0 0
Germany
State/province [66] 0 0
Dresden
Country [67] 0 0
Germany
State/province [67] 0 0
Freiburg im Breisgau
Country [68] 0 0
Germany
State/province [68] 0 0
Hamburg
Country [69] 0 0
Germany
State/province [69] 0 0
Herne
Country [70] 0 0
Germany
State/province [70] 0 0
Langenau
Country [71] 0 0
Germany
State/province [71] 0 0
Ratingen
Country [72] 0 0
Germany
State/province [72] 0 0
Tübingen
Country [73] 0 0
Hong Kong
State/province [73] 0 0
Hong Kong
Country [74] 0 0
Hungary
State/province [74] 0 0
Békéscsaba
Country [75] 0 0
Hungary
State/province [75] 0 0
Budapest
Country [76] 0 0
Hungary
State/province [76] 0 0
Debrecen
Country [77] 0 0
Hungary
State/province [77] 0 0
Gyula
Country [78] 0 0
Hungary
State/province [78] 0 0
Hódmezovásárhely
Country [79] 0 0
Hungary
State/province [79] 0 0
Kaposvár
Country [80] 0 0
Hungary
State/province [80] 0 0
Kecskemét
Country [81] 0 0
Hungary
State/province [81] 0 0
Szeged
Country [82] 0 0
Hungary
State/province [82] 0 0
Székesfehérvár
Country [83] 0 0
Hungary
State/province [83] 0 0
Szolnok
Country [84] 0 0
Hungary
State/province [84] 0 0
Veszprém
Country [85] 0 0
India
State/province [85] 0 0
Ahmedabad
Country [86] 0 0
India
State/province [86] 0 0
Bhubaneswar
Country [87] 0 0
India
State/province [87] 0 0
Hubballi
Country [88] 0 0
India
State/province [88] 0 0
Kolkata
Country [89] 0 0
India
State/province [89] 0 0
Mysuru
Country [90] 0 0
India
State/province [90] 0 0
New Delhi
Country [91] 0 0
India
State/province [91] 0 0
Noida
Country [92] 0 0
India
State/province [92] 0 0
Surat
Country [93] 0 0
Italy
State/province [93] 0 0
Ancona
Country [94] 0 0
Italy
State/province [94] 0 0
Brescia
Country [95] 0 0
Italy
State/province [95] 0 0
Catania
Country [96] 0 0
Italy
State/province [96] 0 0
Milan
Country [97] 0 0
Italy
State/province [97] 0 0
Naples
Country [98] 0 0
Italy
State/province [98] 0 0
Pavia
Country [99] 0 0
Italy
State/province [99] 0 0
Roma
Country [100] 0 0
Italy
State/province [100] 0 0
Rozzano
Country [101] 0 0
Italy
State/province [101] 0 0
Siena
Country [102] 0 0
Italy
State/province [102] 0 0
Udine
Country [103] 0 0
Japan
State/province [103] 0 0
Chiba
Country [104] 0 0
Japan
State/province [104] 0 0
Chuoku
Country [105] 0 0
Japan
State/province [105] 0 0
Hirakata
Country [106] 0 0
Japan
State/province [106] 0 0
Hyogo
Country [107] 0 0
Japan
State/province [107] 0 0
Kitakyushu-shi
Country [108] 0 0
Japan
State/province [108] 0 0
Nagoya
Country [109] 0 0
Japan
State/province [109] 0 0
Osaka
Country [110] 0 0
Japan
State/province [110] 0 0
Oita
Country [111] 0 0
Japan
State/province [111] 0 0
Sanuki
Country [112] 0 0
Japan
State/province [112] 0 0
Sasebo
Country [113] 0 0
Japan
State/province [113] 0 0
Sendai
Country [114] 0 0
Japan
State/province [114] 0 0
Shimotsuga Gun
Country [115] 0 0
Japan
State/province [115] 0 0
Tokyo
Country [116] 0 0
Japan
State/province [116] 0 0
Tsu
Country [117] 0 0
Japan
State/province [117] 0 0
Yokohama
Country [118] 0 0
Malaysia
State/province [118] 0 0
Alor Star
Country [119] 0 0
Malaysia
State/province [119] 0 0
Batu Caves
Country [120] 0 0
Malaysia
State/province [120] 0 0
Ipoh
Country [121] 0 0
Malaysia
State/province [121] 0 0
Johor Bahru
Country [122] 0 0
Malaysia
State/province [122] 0 0
Kuala Lumpur
Country [123] 0 0
Malaysia
State/province [123] 0 0
Seremban
Country [124] 0 0
Mexico
State/province [124] 0 0
Culiacán
Country [125] 0 0
Mexico
State/province [125] 0 0
Guadalajara
Country [126] 0 0
Mexico
State/province [126] 0 0
Mexicali
Country [127] 0 0
Mexico
State/province [127] 0 0
Mexico City
Country [128] 0 0
Mexico
State/province [128] 0 0
Monterrey
Country [129] 0 0
Mexico
State/province [129] 0 0
San Luis Potosí City
Country [130] 0 0
Poland
State/province [130] 0 0
Bialystok
Country [131] 0 0
Poland
State/province [131] 0 0
Bydgoszcz
Country [132] 0 0
Poland
State/province [132] 0 0
Elblag
Country [133] 0 0
Poland
State/province [133] 0 0
Gdynia
Country [134] 0 0
Poland
State/province [134] 0 0
Krakow
Country [135] 0 0
Poland
State/province [135] 0 0
Lodz
Country [136] 0 0
Poland
State/province [136] 0 0
Lublin
Country [137] 0 0
Poland
State/province [137] 0 0
Nadarzyn
Country [138] 0 0
Poland
State/province [138] 0 0
Torun
Country [139] 0 0
Poland
State/province [139] 0 0
Warsaw
Country [140] 0 0
Poland
State/province [140] 0 0
Wroclaw
Country [141] 0 0
Romania
State/province [141] 0 0
Bucharest
Country [142] 0 0
Romania
State/province [142] 0 0
Craiova
Country [143] 0 0
Romania
State/province [143] 0 0
Ia?i
Country [144] 0 0
Romania
State/province [144] 0 0
Râmnicu Vâlcea
Country [145] 0 0
Spain
State/province [145] 0 0
A Coruña
Country [146] 0 0
Spain
State/province [146] 0 0
Córdoba
Country [147] 0 0
Spain
State/province [147] 0 0
L'Hospitalet de Llobregat
Country [148] 0 0
Spain
State/province [148] 0 0
Madrid
Country [149] 0 0
Spain
State/province [149] 0 0
Málaga
Country [150] 0 0
Spain
State/province [150] 0 0
Santander
Country [151] 0 0
Spain
State/province [151] 0 0
Santiago de Compostela
Country [152] 0 0
Spain
State/province [152] 0 0
Seville
Country [153] 0 0
Taiwan
State/province [153] 0 0
Hsinchu
Country [154] 0 0
Taiwan
State/province [154] 0 0
Kaohsiung City
Country [155] 0 0
Taiwan
State/province [155] 0 0
Tainan
Country [156] 0 0
Taiwan
State/province [156] 0 0
Taipei
Country [157] 0 0
Thailand
State/province [157] 0 0
Bangkok
Country [158] 0 0
Thailand
State/province [158] 0 0
Changwat Sara Buri
Country [159] 0 0
Thailand
State/province [159] 0 0
Songkhla
Country [160] 0 0
Turkey (Türkiye)
State/province [160] 0 0
Ankara
Country [161] 0 0
Turkey (Türkiye)
State/province [161] 0 0
Gaziantep
Country [162] 0 0
Turkey (Türkiye)
State/province [162] 0 0
Istanbul
Country [163] 0 0
Turkey (Türkiye)
State/province [163] 0 0
Kocaeli
Country [164] 0 0
Turkey (Türkiye)
State/province [164] 0 0
Konya
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Barnet
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Basingstoke
Country [167] 0 0
United Kingdom
State/province [167] 0 0
Christchurch
Country [168] 0 0
United Kingdom
State/province [168] 0 0
Edinburgh
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Glasgow
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Hereford
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Larbert
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Staffordshire
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Torquay
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Wolverhampton
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Wrexham

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country
Secondary sponsor
Nil

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.